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1. Introduction 
Thyroid disorders are known to involve all the organ systems of the body and the skin is no 
exception. Some dermatological skin findings and diseases may be the first symptoms of 
thyroid disease [1]. Available data suggest that thyroid hormone plays a pivotal role in 
embryonic development of mammalian skin as well as in maintenance of normal cutaneous 
function an adult skin. Thyroid hormone stimulates epidermal oxygen consumption, protein 
synthesis, mitosis, and determination of epidermal thickness [2]. Thyroid hormone is an 
important regulator of epidermal homeostasis. In tissue culture studies using surrogates for 
DNA expression, T 3 has been shown to stimulate growth of both epidermal keratinocytes 
and dermal fibroblastes [3, 4]. In addition, thyroid hormone appears to be necessary for both 
the initiation and maintenance of hair growth and normal secretion of sebum.  
Both hypothyroidism and hyperthyroidism are known to cause skin change. 
Hypothyroidism may result from either inadequate circulating levels of thyroid hormone or 
target cell resistance to hormonal action. Primary hypothyroidism is as a result of glandular 
failure is the most common cause and most frequently result from autoimmune disease [5]. 
In hypothyroidism, the skin is cold, xerotic and pale. The coldness is due to reduced core 
temperature and cutaneous vasoconstriction. The decreased skin perfusion has been 
documented with nail fold capillaroscopy [6]. It has been suggested that the diminished skin 
perfusion is reflex vasoconstriction compensatory to diminished core temperature. The 
diminished core temperature itself may be secondary to reduced thermogenesis [7]. 
Occasionally, purpura may be noted in hypothyroid patients as a result of diminished levels 
of clothing factors and the loss of vascular support secondary to the dermal mucin [8]. The 
dryness of hypothyroid skin results from decreased eccrine gland secretion. The mechanism 
for decreased sweating is not clear although the hypothyroid glands are atrophic on 
histologic examination [9]. Hypohidrosis, possibly accompanied by diminished epidermal 
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sterol biosynthesis, may lead to acquired palmoplantar keratoderma. Xerosis is due to a 
change in skin texture and poor hydratation of the stratum corneum. The skin is rough and 
covered with fine scales. Palms and soles may be quite dry. The epidermis is thin and 
hyperkeratotic, and there is follicular plugging. Because the changes are generalized, they 
can be differentiated from similar alterations in the skin of atopic individuals and keratosis 
pilaris, where the findings are more prominent on the extremities [10]. Hypothyroidism also 
may affect the development of the lamellar granules (Odland bodies), which are vital in the 
establishment of a normal stratum corneum [11]. In hypothyroidism, the skin tends to be 
pale both because of the dermal mucopolysaccharides and dermal water content which alter 
the refraction of light. The name myxedema refers to the associated skin condition caused by 
increased glycosaminoglycan deposition in the skin. Generalized myxedema is still the 
classic cutaneous sign of hypothyroidism. The mucopolysaccharides that accumulate in the 
dermis are hyaluronic acid and chondriotin sulfate. They appear first in the papillary dermis 
and are most prominent around hair follicles and vassels. They separate the collagen 
bundles and there may be some secondary degeneration of collagen [10]. Generally, 
myxedema is diffuse, but focal mucinous papules have been describes. Skin may appear 
swollen, dry, pale, waxy, and firm to the touch. In addition, increased dermal carotene may 
appear as a prominent yellowish discoloration on the palms, soles and nasolabial folds. 
Hypothyroid patients may sometimes suffer Candida folliculitis. It has been theorized that 
because the sebaceous glands of hypothyroid patients secrete decreased sebum relative to 
those of euthyroid persons, the hair follicles may develop a flora with lipophilic organisms, 
which are replaced by Candida albicans (12). The hypothyroid skin heals slowly, and this 
tendency is proportional to the degree of hormone deficiency. In hypothyroidism, hair can 
be dry, coarse, brittle and slow growing. There is both patchy and diffuse loss of scalp hair, 
a very characteristic loss of the outer third of the eyebrow (madarosis), and diminished body 
hair. Pubic and axillary hair may be sparse. The alopecia connected to hypothyroidism may 
be mediated by hormone effects on the initiation as well as the duration of hair growth. 
Massive telogen effluvium may occur when there is abrupt onset of hypothyroidism, and 
the percentage of scalp hairs in telogen is generally increased in hypothyroid states [10]. 
Using DNA flow cytometry, Schell et al. observed that cell proliferation indices were 
reduced in hair bulbs of hypothyroid subjects and increased in hyperthyroidism compared 
with normal values [13]. Hypothyroid patients, especially children, frequently develop long, 
lanugo-type hair on the back, shoulders, and extremities [10]. Diminished sebum secretion 
contributes to the coarse appearance of the hair. Sometimes, hair loss is the only apparent 
symptom of hypothyroidism and the dermatologist is the first to diagnose and treat the 
condition. Nails grow slowly and tend to be thickened, striated and brittle. Onycholysis is 
also associated with hypothyroidism [1]. 
The specific pathophysiology linking hyperthyroidism to classic cutaneous findings remains 
to be well explained (5). In hyperthyroidism, the skin is warm, soft, moist and smooth. The 
epidermis is thin but not atrophic, and the stratum corneum is well hydrated. While the 
smooth skin is an epidermal finding, the warmth is caused by increased cutaneous blood 
flow and the moisture is a reflection of the underlying metabolic state [10]. The warmth is 
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often accompanied by a persistent flush of the face, redness of the elbows, and palmar 
erythema. Hyperhydrosis, especially on palms and soles may be observed. Scalp hair may be 
fine and soft, and may be accompanied by a diffuse nonscarring alopecia. In vitro studies 
suggest increased hair growth rate in thyrotoxicosis. L-Triiodothyronine was shown to 
stimulate proliferation of outer root sheath keratinocytes and dermal papilla cells [14]. 
Hypertrichosis is can be observed in cases of thyroid dermatopathy and may be related to 
alterations in the proteoglycans associated with dermal papilla [15]. Sometimes an early 
symptom of hyperthyroidism is loss of pigment and early gray hair development. Nail 
changes may also occur, characterized by a concave contour accompanied by distal 
onycholysis (Plummer's nails). Hyperpigmentation has been described in thyrotoxic patients 
in both localized and generalized distribution. There is speculation that the hyperpigmentation 
is due to increased release of pituitary adrenocorticotropic hormone compensating for 
accelerated cortisol degradation [16].  Hyperthyroidism may also induce pruritus with or 
without urticaria [17]. Patients with autoimmune mediated thyrotoxicosis may also have 
distinct cutaneous manifestations such as pretibial myxedema and acropachy. Pretibial 
myxedema is the localized thickening of the pretibial skin due to accumulation of acid 
mukopolysaccharides. It usually present with firm nodules and plaques varying in colour 
from pink to purple-brown, and sometimes accompanied by woody induration on extensor 
surfaces. A diffuse brawny edema may be present without nodules. Localized hyperhydrosis 
has been reported in cases of pretibial myxedema. Less common is an elephantiasis nostras 
variant in which the extremity becomes enlarged and covered with verrucous nodules [10]. 
Thickening of the skin of the extensor surface of the forearm (preradial myxedema) has been 
reported [18]. Excessive amounts of hyaluronic acid and chondriotin are present in lesions as 
well as in clinically normal skin [19]. The precise pathogenesis of pretibial myxedema remains 
to be defined. One leading theory is that pretibial fibroblasts are the target for antithyroid 
antibodies. After stimulation by thyroid autoantibodies, fibroblasts may produce excess 
glukosaminglycans [5]. Other theories have implicated T cells as the primary effector of 
dermopathy. T-cells may interact with an autoantigen that is either identical or cross-reactive 
with a thyroid autoantigen in the dermis. In turn, this may induce secretion of cytokines such 
as glycosaminoglycan-stimulatory lymphokine, interleukin1, tumor necrosis factor, and 
gamma interferon, which activate fibroblasts to secrete hyaluronic acid and chondriotin sulfate 
[20]. Thyroid acropachy consist of the triad of digital clubbing, soft-tissue swelling of the 
hands and feet, and characteristic periostal reactions. The vast majority of cases are associated 
with Graves' disease, although it has been reported to occur in Hashimoto's thyroiditis. 
Scleromyxedema has been reported in the setting of hyperthyroidism. This rare entity is 
comprised of numerous firm, white, yellow, or pink papules scattered on the face, trunk, and 
extremitates. Cutaneous lesions are the result of accumulation of acid mucopolysaccharides, 
mostly hyaluronic acid, in the dermis, accompanied by large fibrocytes [5]. 
Skin manifestations of thyroid dysfunction may be divided into two main categories: (I) 
direct action of thyroid hormone on skin tissues, and (II) autoimmune skin disease 
associated with thyroid dysfunction of autoimmune etiology. Direct thyroid hormone action 
on skin is mediated through thyroid hormone receptor (TR). All three widely recognized 
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thyroid hormone binding isoforms of TR have been identified in skin tissues [14, 21]. TRs 
have been detected in epidermal keratinocytes, skin fibroblasts, hair arrector pili muscle 
cells, sebaceous gland cells, vascular endothelial cells, and a number of cells types that make 
up the hair follicle [9]. The demonstration of TR expression in hair follicle cells indicates that 
thyroid hormone can affect hair growth directly, rather than through an intermediate 
mechanism such as a general metabolic status [22]. In addition, several thyroid hormone 
responsive genes have been identified in skin.  
When thyroid disease is of autoimmune etiology, additional skin findings may be evident 
which reflect associated autoimmune disease [9]. Patients with autoimmune thyroid disease 
are at increased risk for other autoimmune diseases, both tissue-specific and generalized. In 
autoimmune disease such as Graves' disease and Hashimoto's thyroiditis the skin 
manifestations may be related to either thyroid hormone levels themselves or to associated 
T and/or B cell abnormalities [23]. A list of autoimmune conditions apparent when 
examining the skin includes alopecia areata, vitiligo, chronic urticaria, bullous disorders, 
connective tissue diseases and palmoplantar pustulosis. 
There is convincing evidence of a significant association between thyroid autoimmunity and 
skin disorders. Most commonly reported cutaneous disorder related with thyroid diseases is 
alopecia areata, which have especially autoimmune etiology. 
2. Thyroid autoimmunity in patients with alopecia areata 
2.1. Introduction 
Alopecia areata (AA) is a clinical condition characterized by well circumscribed, round, or oval 
patches of hair loss on the scalp or other parts of the body. Sometimes, alopecia totalis (AT), 
loss of all scalp hair, or alopacia universalis (AU), loss of all body hair, may develop. This 
disorder affects both sexes equally and occurs at all ages, although children and young adults 
are affected most often. The etiopathogenesis of AA is still unclear, but there is evidence that 
autoimmunity and endocrine dysfunction may be involved [24-26]. The autoimmune etiology 
has been proposed on the basis of its association with various autoimmune diseases, the 
presence of autoantibodies and various underlying immune abnormalities in the affected sites 
of these patients [27, 28]. One of the main associations is with thyroid abnormalities. This 
association was further supported by an increased incidence of abnormal thyroid structure, 
function tests and/or presence of thyroid autoantibodies found in many studies [29-32]. 
The aim of this study was to determine the prevalence of thyroid autoimmunity in patients 
with AA. 
2.2. Patients and methods 
The study included 70 patients with AA (40 female and 30 male). A detailed history and 
examination were taken in all study subjects, including patients age, age at onset, duration 
of disease, associated diseases, history of thyroid disorders and the extent and severity of 
 
Thyroid Autoimmunity in Patients with Skin Disorders 301 
disease. The diagnosis of AA was made on clinical grounds. Skin biopsy was performed in 
selected cases. No patient was diagnosed before this study as having any type of thyroid 
dysfunction. The control group consisted of 70 volunteers (40 female and 30 male) who had 
skin diseases other then AA or autoimmune disorders. Blood samples were taken and a 
physical examination and thyroid sonography was performed. All subjects gave their 
informed consent in accordance with the requirements of the institutional Ethichs 
Committee. Thyroid autoantibodies (thyroglobulin antibody, anti-Tg, and thyroid 
peroxidase antibody, anti-TPO) and thyroid hormones (thyroxine (T4), triiodthyronine (T3) 
and thyroid stimulating hormone (TSH) were measured in all subjects. Total T4 (normal 
range: 70-180 nmol/L) and total T3 (normal range: 1.3-3.3 nmol/L) were measured by use of 
radioimmunoassay (RIA); TSH (normal range: 0.3-4.2 mlU/L) was determined by use of 
immunoradiometric assay (IRMA) (BRAHMS Aktiengesellshaft, Hennigsdorf, Germany). 
Serum levels of anti-Tg (threshold value: 115 IU/mL) and anti-TPO (borderline value: 34 
IU/mL) were measured by use of electrochemiluminiscence immunoassay (ECLIA) 
according to standard protocols (COBAS, Roche Diagnostics GmbH, Mannheim, Germany). 
Baseline clinical characteristics for the two groups were compared with the use of Student’s 
t-test for continuous variables, the chi-square test or Fisher’s exact test (two-sided) for 
categorical variables, as appropriate. Data were considered statistically significant at P <0.05. 
Statistical analyses were performed using MedCale for Windows, version 11.4.1.0 (MedCale 
Software, Mariakerke, Belgium). 
2.3. Results 
We performed a cross-sectional study in 70 consecutive patients with alopecia areata and 70 
age- and sex-matched controls. Demographic data of patients and controls are shown in 
Table 1. The mean (SD) age of the patient and control groups was 40.39 (±14.39) and 40.71 
(±15.30), respectively (P = 0.896). The onset of AA occurred in 14 (20%) of the patients before 
16 years of age, 3 (4.28%) patients had AA more than 10 years. The duration of alopecia 
areata ranged from 1 to 150 months. A family history of the same disease was present in 7 
(10%) patients. According to the clinical type of AA, 13 patients had unilocular lesion, 37 
patients had multilocular lesions, 12 alopecia totalis and 8 alopecia universalis (Table 2).  
Thyroid functional abnormalities were found in 8 (11,43%) patients. In the control group 
only one patient had abnormalities in hormonal status. 
Hypoechogenic thyroid tissue was seen in 7 (10%) patients who all had elevated levels of 
thyroid autoatibodies. The thyroid gland was enlarged in 5 (7.14%) patients. Goitre was 
diagnosed in 4 (5.71%) cases. The ultrasound examination of the thyroid gland in control 
group was interpreted as normal in 64 (91.42%), and 6 (5.45%) volunteers had small simple 
goiter. Thyroid volume did not differ significantly between the study patients and the 
controls (p>0.05). 
In patients with alopecia areata anti-Tg titers were ranging from 11.10 to 915.30 IU/mL and 
anti-TPO antibody titers from 5.10 to 714.40 IU/mL. In control group anti-Tg titers were 
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ranging from 10.00 to 153.00 IU/mL, and anti-TPO antibody titers from 4.40 to 129.00 IU/mL. 
Anti-Tg antibody in 16 (23%) patients, anti-TPO antibody in 21 (30%) and both anti-Tg and 
anti-TPO antibodies in 13 (19%) were higher than the normal antibody titres. In the control 
group, one subject (1%) had positive anti-Tg and one volunteer (1%) had positive anti-TPO. 
The frequency of thyroid autoantibodies was significantly higher in alopecia areata patients 
than in control group (Table 3). 
A Chi-square test for independence (with Yates Continuity Correction) indicated significant 
association between higher values of anti-Tg (values more than 115 IU/ml) and alopecia 
areata, χ2 (1, n=140)= 13.123, P=0.0003. 
A Chi-square test for independence (with Yates Continuity Correction) indicated significant 
association between higher values of anti-TPO (values more than 34 IU/ml) and alopecia 
areata, χ2 (1, n=140)=19.468, P<0.0001. 
 
 Alopecia areata group n 
(%) 
Control group n 
(%) 
P 
Men, n (%) 30 (43) 30 (43)  
Women, n (%) 40 (57) 40 (57)  
Age range, years 17-66 16-66  
Age, mean years (SD) 40.39 (14.39) 40.71 (15.30) 0.896 
Table 1. Demographic data of patients (Alopecia areata group) and volunteers (Control group) 
Mean age of onset (SD) (year) 38.14 (14.61) 
Age of onset range (year) 14-65 
Mean duration (SD) (month) 21.93 (30.69) 
Duration Range (month) 1-150 
Type of alopecia areata n, (%)  
 Unilocularis 13 (19)  
 Multiloculares 37 (53)  
 Universalis 8 (11)  
 Totalis 12 (17)  
Table 2. Clinical characteristics of alopecia areata patients 
 anti-Tg (threshold value115 IU/ml) anti-TPO (threshold value 34 IU/ml) 
Group Negative n(%) Positive n(%) Negative n(%) Positive n(%) 
Alopecia areata 54 (77) 16 (23) 49 (70) 21(30) 
Control 69 (99) 1 (1) 69 (99) 1 (1) 
Total 123 (88) 17 (12) 118 (84) 22 (16) 
Difference n (%) 15 (22) 20 (29) 
χ2, P χ2=13.123, P=0.0003 χ2=19.468, P<0.0001 
Table 3. The frequencies of positive detectable thyroid autoantibody (anti-Tg and anti-TPO) 
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Scheme 1. Differences of frequencies positive/negative values of anti-Tg (threshold value115 IU/ml) 
between groups 
 
Scheme 2. Differences of frequencies positive/negative values of anti-TPO (threshold value 34 IU/ml) 
between groups 
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 anti-Tg 
(threshold value115 IU/ml) Types of alopecia areata (P) 
Type of 
alopecia areata Negative n Positive n Total Multiloculares Totalis Universalis 
Unilocularis 12 1 13 0.662246 0.160248 0.047472* 
Multiloculares  30 7 37 N/A 0.426673 0.085080 
Totalis 8 4 12 N/A N/A 0.647916 
Universalis 4 4 8 N/A N/A N/A 
Total 54 16 70    
Table 4. The frequencies of positive detectable thyroid autoantibody (anti-Tg) and differences between 
types of alopecia areata 
A Fisher’s exact indicated significant association between higher values of anti-Tg (values 
more than 115 IU/ml) and some types of alopecia areata, Universalis vs Unilocularis 
(P=0.047472) (Table 4.) 
 
Scheme 3. Types of alopecia areata and frequencies positive/negative values of anti-Tg (threshold 
value115 IU/ml) 
A Fisher’s exact indicated significant association between higher values of anti-TPO (values 
more than 34 IU/ml) and some types of alopecia areata: Unilocularis vs Totalis (P=0.005217), 
Unilocularis vs Universalis (P=0.000069) and Multiloculares vs Universalis (P=0.000925) 
(Table 5). 
Types of alopecia areata and frequencies positive/negative values of 




















Thyroid Autoimmunity in Patients with Skin Disorders 305 
 anti-TPO 
(threshold value 34 IU/ml) Types of alopecia areata (P) 
Type of 
alopecia areata Negative n Positive n Total Multiloculares Totalis Universalis 
Unilocularis 13 0 13 0.092788 0.005217* 0.000069* 
Multiloculares  29 8 37 N/A 0.075803 0.000925* 
Totalis 6 6 12 N/A N/A 0.157688 
Universalis 1 7 8 N/A N/A N/A 
Total 49 21 70    
Table 5. The frequencies of positive detectable thyroid autoantibody (anti-TPO) and differences 
between types of alopecia areata 
 
Scheme 4. Types of alopecia areata and frequencies positive/negative values of anti-TPO (threshold 
value 34 IU/ml) 
2.4. Discusion 
Alopecia areata is an ancient disease that was known to Egyptians even in the pre-Christian 
time [33]. Despite its long history, our knowledge is actually limited. Today, AA is 
hypothezed to be an autoimmune, organ specific T-cell mediated reaction directed against 
an unknown autoantigen of the hair follicle. T lymphocytes that have been shown to be 
oligoclonal and autoreactive are predominantly present in the peribulbous inflammatory 
infiltrate [34]. Although the skin is the primary location of the clinical phenotype, the 
determination of disease expression involves a complex interplay between different 
Types of alopecia areata and frequencies positive/negative
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inflammatory cell subsets in the skin, skin draining lymphonodes, and spleen of the affected 
individuals [35]. 
Clinical association with AA has known for many years. AA frequently occurs in association 
with other autoimmune disorders such as vitiligo, lupus erythematosus, pernicious anemia 
and others [34, 36-38]. Among endocrine disorders, thyroid diseases are the commonest that 
has been described as associated with AA, but the issued values were different. In the 
greatest study reported till now, Muller and Winkelmann have found the evidences of 
different types of thyroid disease in 8% of 736 patients in compare to less than 2% of the 
control population in North America [39]. Broniarczyk-Dyla et al. observed abnormalities of 
thyroid structure and function in even 78% of AA patients [40]. Conversely, Puavilai et al. 
estimated that the prevalence of thyroid disease is relatively low (7.2%) and was not 
statistically different from the control group [41]. 
In accordance to previous studies, current study reported a high frequency of thyroid 
diseases in AA patients. We detected elevated anti-Tg in 16 (23%) and elevated anti-TPO in 
21 (30%) of patients with AA. Compared with the control group, the frequency of the both 
anti-Tg and anti-TPO antibodies was significantly higher in those with AA. Statistically 
significant difference was also found in values of anti-Tg and anti-TPO between patients 
with different clinical type of the disease. The highest anti-Tg concentrations were observed 
in patients with alopecia universalis. Patients with thyroid diseases were on an average 
older and reported longer duration, but the results were not statistically significant. These 
results are consistent with a clinical study performed by Seyrafi et al. [32]. They analyzed 
serum TgAb level in 123 Iranian patients with AA and found it to be elevated in 29.3% of 
study patients. Grandolfo et al. observed the presence of thyroid autoantibodies in even 44% 
of AA patients [42]. Goh et al. also confirmed the frequent coexistence of AA and thyroid 
abnormalities [43]. They found 19% of probands with thyroid disease including simple 
goitre, Grave´s disease and Hashomoto´s thyroiditis. Our findings showed that the 
frequency of anti-TPO was more significant than anti-Tg. This antibody, historically referred 
to as the antimicrosomal antibody, is established as a sensitive tool for the detection of early 
subclinical autoimmune thyroid diseases and identification of at-risk cases for autoimmune 
thyroid diseases [44]. Nordyke et al. reported that anti-TPO antibody tends to have more 
correlation than does the anti-Tg antibody [45]. 
Alopecia areata offers many benefits as a model for the study of autoimmunity, in that it can 
be used to identify the contributing roles of immunogenetics and neuroendocrine factors in 
the initiation and propagation of autoimmune disease [24]. 
The study revealed a significant association between AA and thyroid disease and showed 
the tests used to detected thyroid autoantibodies to be relevant in patients with AA. Further 
exploration of this relationship in clinical setting and at a molecular level may help in the 
understanding of the pathogenesis of both diseases. 
3. Conclusions 
Thyroid autoimmunity is the most prevalent autoimmune condition in the general 
population, and is also associated with various skin diseases. The evidence is strong for the 
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association with alopecia areata. Although their etiology is still unclear, the autoimmune 
hypothesis is most commonly accepted. 
The nature of the relationship between anti-thyroid autoimmunity and the pathogenesis of 
autoimmune diseases is presently unknown. Some authors have shown that anti-Tg 
antibodies can form immune complexes [46], and anti-microsomal antibodies not only bind 
to thyroid peroxidase but also modulate natural killer cell activity in autoimmune 
thyroiditis [47]. Possible explanations for the relationship of these autoimmune diseases 
include: (1) immunomodulatory effects of antithyroid antibodies, (2) molecular mimicry 
between thyroid and disease-specific epitopes, and (3) genetic link between anti-thyroid 
autoimmunity and the susceptibility to autoimmune disease [48]. It is a multidisciplinary 
problem requiring cooperation of specialists in different fields of medicine. Both 
dermatologists and endocrinologists have to inquire their patients about the family history 
of autoimmune diseases and to look for associated autoimmune disorders. 
This chapter is an attempt to update the current knowledge about the relationship between 
the thyroid and the skin diseases. Although cutaneous manifestations of autoimmune 
thyroid diseases are well described and thyroid hormone is known to regulate the 
development and function of skin, a better understanding of these processes is needed. 
Author details 
Emina Kasumagic-Halilovic* 
Department of Dermatovenerology, Sarajevo University Clinical Center, Sarajevo,  
Bosnia and Herzegovina 
Begler Begovic 
Department of Clinical Pharmacology, Sarajevo University Clinical Center, Sarajevo,  
Bosnia and Herzegovina 
4. References 
[1] Mullin GE, Eastern JS (1986) Cutaneous signs of thyroid disease. Am Fam Physican. 34: 
93-98. 
[2] Mullin GE, Eastern JS (1986) Cutaneous consequences of accelerated thyroid function. 
Cutis. 37: 109-114. 
[3] Safer JD, Crawford TM, Fraser LM, Hoa M, Ray S, Chen TC at al. (2003) Thyroid 
hormone action on skin: Diverging effects of topical varsus intraperitoneal 
administration. Thyroid. 13: 159-165. 
[4] Holt PJA (1978) In vivo responses of the epidermis to triiodthyronine. J Invest Derm. 71: 
202-204. 
[5] Leonhardt JM, Heyman WR (2002) Thyroid disease and the skin. Dermatol Clin. 20:473-
481. 
                                                                 
* Corresponding Author 
 
Thyroid Hormone  308 
[6] Pazos-Moura CC, Moura EG, Breitenbach MMD et al. (1998) Nailfold capillaroscopy in 
hypothyroidism: blood flow velocity during rest and postocclusive reactive hyperemia. 
Angiology. 49: 471 
[7] Silva JE (2003) The termogenic effect of thyroid hormone and its clinical implications. 
Anals of Internal Medicine. 139. 205-213. 
[8] Christianson HB (1976) Cutaneous manifestations of hypothyroidism including purpura 
and ecchymoses. Cutis. 17: 45. 
[9]  Safer JD (2011) Thyroid hormone action on skin. Dermato Endocrinology 3: 211-215. 
[10] Freinkel RK (1993) Cutaneous manifestations of endocrine disease. In: Fitzpatrick TB, 
Eisen AZ, Wolff K, Freedberg IM, Austen KF, editors. Dermatology in general 
medicine. McGraw-Hill, Inc. pp 2113-2131. 
[11] Hanley K, Devaskar UP, Hicks SJ et al. (1997) Hypothyroidism delays fetal stratum 
corneum development in mice. Pediatr Res. 42: 610. 
[12] Dekio S, Imaoka C, Jidoi J (1987) Candida folliculitis associated with hypothyroidism. 
Br J Dermatol. 117: 663. 
[13] Schell H, Kiesewetter F, Seidel C et al. (1991) Cell cycle kinetiks of human anagen scalp 
hair bulbs in thyroid disorders determined byDNA flow cytometry. Dermatologica. 
182: 23-26. 
[14] Ahsan MK, Urano J, Kato S, Oura H, Arase S (1998) Immunohistochemical localization 
of thyroid hormone nuclear receptors in human hair follicles and in vitro effect of L-
triiodothyronine on cultured cells of hair follicles and skin. J Med Invest. 44: 179-184. 
[15] Westgate GE, Messenger AG, Watson LP, et al. (1991) Distribution of proteoglycans 
during the hair growth cycle in human skin. J Invest Dermatol. 96: 191. 
[16] Diven DG, Gwinup G, Newton RC (1989) The thyroid. Dermatol Clin. 7: 547-557. 
[17] Ai J, Leonhardt JM, Heymann WR (2003) Autoimmune thyroid diseases: etiology, 
pathogenesis, and dermatologic manifestations. J Am Acad Dermatol. 48: 641-659. 
[18] Wortsman J, Dietrich J, Traycoff RB, Stone S (1981) Preradial myxedema in thyroid 
disease. Arch Dermatol. 117: 635-638. 
[19] Bierewaltes WH, Bollet AJ (1959) Mucopolysaccharide content of skin in patients with 
pretibial myxedema. J Clin Invest. 38: 945 
[20] Weetman AP (2001) Determinants of autoimmune thyroid disease. Nat Immunol. 2: 
769-770. 
[21] Billoni N, Buan B, Gautier B, Gaillard O, Mahe YF, Bernhard BA (2000) Thyroid 
hormone receptor beta-1 is expressed in the human hair follicle. Br J Dermatol. 142: 645-
652. 
[22] Messenger AG (2000) Thyroid hormone and hair growth. Br J Dermatol. 142: 631-635. 
[23] Burman KD, McKinley-Grant L (2006) Dermatologic aspects of thyroid disease. Clin 
Dermatol. 24: 247-255. 
[24] Gilhar A, Paus R, Kalish R (2007) Lymphocytes, neuropeptides, and genes involved in 
alopecia areata. J Clin Invest. 117: 2019-27. 
[25] Alexis AF, Dudda-Subramanya R, Sinha AA (2004) Alopecia areata: autoimmune basis 
of hair loss. Eur J Dermatol. 14(6): 364-70. 
 
Thyroid Autoimmunity in Patients with Skin Disorders 309 
[26] Milgraum SS, Mitchell AJ, Bacon GE, Rasmusen JE (1987) Alopecia areata, endocrine 
function, and antibodies in patients 16 years of age or younger. J Am Acad Dermatol. 
17: 57-61. 
[27] McDonagh AJG, Messenger AG (1996) The pathogenesis of alopecia areata. Dermatol 
Clin. 14: 661-70. 
[28] Tobin DJ, Orentreich N, Fenton DA, Bystrin JC (1994) Antibodies to hair follicles in 
alopecia areata. J Invest Dermatol. 102: 721-4. 
[29] Lewinski A, Broniarczyk-Dyla G, Sewerynek E. Zerek-Melen G, Szkudlinski M (1990) 
Abnormlities in structure and function of thyroid gland in patients with alopecia areata. 
J Am Acad Dermatol. 23: 768-9. 
[30] Kasumagic-Halilovic E (2008) Thyroid autoimmunity in alopecia areata. Acta 
dermatovenerol Croat. 16(3): 123-25. 
[31] Kurtev A, Ilev E (2005) Thyroid autoimmunity in children and adolescents with 
alopecia areata. Int J Dermatol. 44: 457-61. 
[32] Seyrafi H, Akhiani M, Abbasi H, Mirpour S, Gholamrezanezahad A (2005) Evaluation 
of the profile of alopecia areata and the prevalence of thyroid function test 
abnormalities and serum autoantibodies in Iranien patients. BMC Dermatol. 5: 11-6. 
[33] Ebel B (1937) The papyrus Ebers: The greatest Egyptian document. Copenhagen: Leivin 
and Munksgaard. 
[34] Hordinsky M, Ericson M (2004) Autoimmunity: Alopecia areata. J Invest Dermatol 
Symp Proc. 9: 73-8. 
[35] McElwee KJ, Hoffman R, Freyschmidt-Paul P, Wenzel E, Kissling S, Sundberg JP (2002) 
Resistence to alopecia areata in C3H/HeJ mice is associated with increased expression of 
regulatory cytokines and failure recruit CD4+ and CD8+ cells. J Invest Dermatol. 119: 
1426-33. 
[36] Gopal KV, Rama Rao GR, Kumar YH, Appa Rao MV, Vasudev P, Strikant (2007) 
Vitiligo: A part of a systemic autoimmune process. Indian J Dermatol Venereol Leprol. 
73(3): 162-65. 
[37] Werth VP, White WL, Sauchez MR, Franks AG (1992) Incidence of alopecia areata in 
lupus erythematosus. Arch Dermatol. 128(3): 368-71. 
[38] Madani S, Shapiro J (2000) Alopecia areata update. J Am Acad Dermatol. 549-66. 
[39] Muller SA, Winkelmann RK (1963) Alopecia areata. Arch Dermatol. 88: 290-97. 
[40] Broniarczyk-Dyla G, Lewinski A, Zerek-Melen G, Sewerynek E, Wozniacka A (1989) 
Abnormalities of structure and function of the thyroid in patients with alopecia areata  
Przegl Dermatol. 76: 416-21. 
[41] Puavilai S, Puavilai G, Charuwichitratana S, Sakuntabhai A, Sriprachya-Anunt S. 
Prevalence of thyroid diseases in patients with alopecia areata. Int J Dermatol 1994; 
33(9): 632-3. 
[42] Gandoldolfo M, Biscazzi AM, Pipoli M (2008) Alopecia areata and autoimmunity. G Ital 
Dermatol Venereol. 143(5): 277-81. 
[43] Goh C, Finkel M, Christos PJ, Sinha AA (2006) Profile of 513 patients with alopecia 
areata: association of disease subtypes with atopy, autoimmune disease and positive 
family history. J Eur Acad Dermatol Venereol. 20: 1055-60. 
 
Thyroid Hormone  310 
[44] Kemp EH (2004) Autoantibodies as diagnostic and predictive markers of vitiligo. 
Autoimmunity. 37:287-90. 
[45] Nordyke RA, Gilbert FI Jr, Miyamoto LA, Fleury KA (1993) The superiority of 
antimicrosomal over antithyreoglobulin antibodies for detecting Hashimoto's 
thyroiditis. Arch Intern Med. 153(7): 862-65. 
[46] Dawe K, Hutchings P, Champion B, Cook A, Roitt I (1993) Autoantigens in thyroid 
diseases. Springer Semin Immunopathol. 14: 285-307. 
[47] Robert DU (1991) The pathogenesis of autoimmune thyroiditis. N Engl J Med. 324: 278-
279. 
[48] Szyper-Kravitz M, Marai I, Shoenfeld Y (2005) Coexistence of thyroid autoimmunity 
with other autoimmune diseases: friend or foe? Additional aspects on the mosaic of 
autoimmunity. Autoimmunity. 38: 247-255. 
